[K-Beauty Hotspots, Part 1] The K-Pharmacy Tour Is Booming. The Law Just Moved the Other Way

Foreign tourists line up outside ordinary neighborhood pharmacies in Myeongdong and Hongdae. They're not there for cold medicine. They come with acne ointments, skin-barrier creams, and scar-repair balms — items pulled straight from a "Korean pharmacy must-buys" list saved on their phone before the trip. In May, foreign card spending in Korea hit KRW 2.12 trillion for the first time ever, and pharmacies posted the fastest growth of any category, at 206%. Skincare and massage services (154%) and dermatology clinics (86%) followed. Yet this explosive demand isn't flowing to chains like Daiso or Olive Young — it's flowing to independent pharmacies that are, by law, blocked from ever becoming a chain. And in a striking coincidence, the National Assembly passed a law during this exact same period that tightens that block even further.

What's Happening — Pharmacies Have Become a K-Beauty Shopping Destination

The Instagram hashtag #약국화장품 ("pharmacy cosmetics") has passed 20,000 posts, and "Korean pharmacy must-buy" videos on YouTube and Xiaohongshu rack up tens of thousands of views. Tourists save this content before they ever land in Korea, then walk straight to the register with it. A tourist from Hong Kong said, "You can't get spot patches this cheap back home." A tourist from Japan said, "Korean products are cheaper than Japanese ones and work better."

The numbers back this up. Foreign medical and healthcare spending rose from KRW 223.3 billion in H1 2023 to KRW 889.6 billion in H1 2024, with pharmacies accounting for 60% of that. As of this May, foreign medical spending hit an all-time high of KRW 251.1 billion (up 74.6% year over year), and pharmacies accounted for 7 out of every 10 medical transactions (69.8%). Sales of Dong-A Pharmaceutical's three topical skin-treatment brands (Noscana, Acnon, Melitoning) jumped from KRW 18.4 billion in H1 2022 to KRW 35.5 billion in H1 last year. Lee Eun-hee, a professor of consumer science at Inha University, explains that "pharmacy-brand cosmetics give consumers the same sense of trust as a dermatologist's prescription." Add in the overlap with post-procedure recovery and soothing products bought at pharmacies, and dermatology treatments and pharmacy shopping are merging into a single travel itinerary — the dermatology side of this boom and duty free's response strategy are covered separately in Part 2.

Key Insight #1 — By the Usual Playbook, This Boom Should Be Turning Into a Chain

When demand for a specific retail category explodes this fast, the normal next step is chain consolidation and standardization. That's how Olive Young came to dominate the H&B market, and how Daiso absorbed low-price retail — standardize multilingual staffing, expand store count around tourist zones, and build out tax-refund infrastructure all at once.

Pharmacies can't take that path. The Pharmacy Act's "one pharmacist, one pharmacy" principle blocks it. Only a licensed pharmacist can open a pharmacy, and in principle, one pharmacist can open and operate only a single pharmacy. The rule exists to keep capital from infiltrating pharmacy operations and eroding their public-interest function — a safeguard meant to keep a pharmacist's individual expertise and judgment from being subsumed by capital logic. As a result, the "hot" tourist pharmacies of Myeongdong and Hongdae are all completely separate businesses, each run by its own individual pharmacist. Tourist-service manuals, tax-refund registration, multilingual signage — every one of these has to be built out pharmacy by pharmacy, individually.

Key Insight #2 — And Right at This Moment, the National Assembly Tightened That Block Further

This is where the real story of this piece lives. On April 23, the National Assembly's plenary session passed an amendment to the Pharmacy Act. The existing law already stated that a pharmacist "may open only one pharmacy," but the amendment rewrote that to: a pharmacist "may not open or operate two or more pharmacies under any name." The change closes off not just opening a second pharmacy, but effectively operating one too — and by adding "under any name," it explicitly shuts down workaround structures as well. The trigger was the recent spread of "network pharmacies" — not official franchises, but groups sharing a brand and functioning as a single system in practice through a shared management-support entity. The amendment takes effect six months after promulgation.

In other words, at the exact moment foreign tourist demand is exploding at the level of individual pharmacies, the National Assembly targeted and shut down the one channel that could have organized that demand at scale — a structure combining capital and organization into a network. These two policy directions didn't collide by design; they're two currents moving toward entirely different goals — protecting pharmacist expertise for patient safety versus stimulating tourism spending — that happened to cross paths, moving in opposite directions, at the same moment. No coverage has connected these two threads until now.

Key Insight #3 — The Legal Workaround That's Still Standing: MSO

That doesn't mean capital is shut out of this market entirely. The hospital and dermatology-clinic industry found a path years ago — the MSO, or Management Service Organization. Gangnam dermatology clinic networks and dental-hospital alliances have long consolidated marketing, payroll, facility management, and joint purchasing under an MSO entity to cut costs, and use of this structure has grown roughly 180% over the past five years. The same principle applies to pharmacies. Rather than "opening or operating" a pharmacy, an MSO is a service entity that handles non-pharmacy work — HR, accounting, marketing and PR, facilities and inventory management — so the pharmacist who holds the license can focus on the actual pharmacy work: dispensing and patient counseling. What the Pharmacy Act blocks is "opening or operating a pharmacy," not "providing management-support services to a pharmacy" — and that gap is currently the one legal scale-up route left standing.

But that gap is narrow, and it collapses the moment it's crossed. If an MSO takes a share of pharmacy profits (revenue-sharing), directly funds pharmacy operating capital (capital provision), or decides on hiring and firing pharmacy staff — that's no longer "management support." It becomes de facto "operational control," and crosses into what's prosecuted as an illegally capital-controlled pharmacy — commonly known in Korea as a "front-operator pharmacy." For an MSO to function legally, its arrangement has to be strictly a fixed-fee service contract, avoiding any form of compensation tied to the pharmacy's revenue or profit.

That gap is narrowing further, too. Following the April amendment's broadened definition of "opening and operating," Democratic Party lawmaker Jeon Jin-suk plans to introduce a follow-up bill (July 10, 2026) targeting so-called "warehouse-style pharmacies." The bill would let local government heads examine contract details with landlords, capital providers, and other financially interested parties as part of pharmacy registration review, and reject an application outright if the contract contains clauses on "allocation or distribution of operating performance" or "restrictions on independent business conduct." If an MSO contract has structured its fee as revenue-linked, this single provision could be enough to block the pharmacy's registration entirely.

Business Impact — Blocked From Chains, Capital Routes Through "MSO and Brand" Instead

With chain consolidation blocked by law, capital and pharmaceutical companies have found two workarounds. One is product branding. Dong-Kook Pharmaceutical has rolled out its pharmacy-exclusive brand "Madeca Pharmacia," and Il-Yang Pharmaceutical its "Dr. Frimetic," starting to tie individual pharmacies together under a shared brand identity. The other is the MSO. While it can't own or operate pharmacies directly, setting up an MSO entity to provide multilingual staffing, tourist-zone location analysis, tax-refund registration on behalf of the pharmacy, and joint marketing and purchasing — all for a fixed fee — can tie individual pharmacies together into a de facto network effect through contracts. It's capital building economies of scale not through "store ownership" but through "SKUs and service contracts."

The infrastructure gap is widening too. Tax refunds only work once an individual pharmacy applies for foreign duty-free retailer status with its local tax office and signs a separate contract with a refund agent. That inevitably creates a tourist-revenue gap between pharmacies already registered, like those in Myeongdong and Hongdae, and those that haven't even applied yet — and this registration process is exactly the kind of service an MSO can attach itself to first. But once the amended Pharmacy Act takes effect (six months after promulgation) and, if Rep. Jeon's bill passes, registration review gets stricter at the same time, even the loosely structured MSO contracts running today will need re-examination. Meanwhile, tourist demand keeps growing, even as the legal organizational infrastructure needed to capture it demands increasingly narrow and precise design.

Key Insight #4 — Why Duty Free's "Taxable Space" Could Be the Next Stage

The capital most ready to move first into this market may, surprisingly, be duty free. The industry is in the middle of a structural crisis. Shinsegae Duty Free closed its Busan store (January 24, 2025), and Shilla and Shinsegae both returned their Incheon Airport T1 DF1/DF2 concessions, each on the hook for roughly KRW 190.0 billion in penalty fees. Lotte Duty Free has bet on diversification as its way out — reasoning that payback-driven perks alone can't hold customers, and that "the longer people stay, the more likely they are to buy," it has kept adding experiential elements. Its renovation of the downtown Ginza duty-free store in Tokyo, which doubled the taxable, non-bonded floor space so local residents could shop there too, follows the same logic.

Layer K-pharmacy-tour demand onto that trend and the picture lines up. Duty-free stores already draw large volumes of foreign tourists who spend real dwell time on-site. Bring in a pharmacy tenant, and there's another lever for converting that traffic into sales. The catch is location — pharmacies can't operate inside a duty-free store's bonded sales area (the space licensed by Korea Customs for duty-free goods specifically). Pharmaceuticals aren't a duty-free category to begin with, and the bonded-area license itself separately regulates floor area and business mix. But duty-free store buildings already coexist with taxable, non-bonded leased space outside the bonded zone. Incheon Airport T2's "Gourmet Bridge" food court is the clearest precedent — operating as a regular taxable leased space rather than a duty-free-licensed zone, and driving dwell time and revenue as F&B. A pharmacy leasing space in that same taxable zone runs into no obstacle under customs law or bonded-area regulation.

Of course, the Pharmacy Act's constraints apply to duty-free operators just as much as anyone else. A duty-free operator can't open or operate a pharmacy directly — it can only act as a landlord leasing taxable space, or, as covered above, as an MSO-style service provider handling multilingual support, tax-refund registration, and marketing on the pharmacy's behalf. And this is exactly where a familiar retail-industry habit becomes a trap. The method large marts and malls currently use to land oversized pharmacies as anchor tenants is revenue-linked rent. Cheongnyangni MBB (a 58-pyeong, roughly 192 sqm pharmacy inside a 1,100-pyeong, roughly 3,636 sqm mixed complex), Homeplus Geumcheon, Starfield Village Unjeong, Yongsan Jeonja Land's warehouse-style pharmacy — commercial landlords desperate to rebuild foot traffic are competing on aggressive terms to land these tenants. But within the pharmacy industry, revenue-linked rent has already become the center of debate over whether it counts as "rent" or "involvement in management." A structure where the landlord's income rises alongside the pharmacy's revenue is open to interpretation as external capital having a direct economic stake in the pharmacy's operating performance — and if Rep. Jeon's bill passes, any contract containing a clause on "allocation or distribution of operating performance" becomes, by itself, grounds for rejecting the pharmacy's registration. This is exactly why duty-free operators can't simply copy the tenant-acquisition formula they use in other categories and apply it to pharmacies.

Key Insight #5 — So the Answer for Duty Free Is "Lease, Not Build"

The question duty-free operators should be asking here is "build a new MSO, or just lease the space?" In the pharmacy channel, the answer is relatively clear — because the "off-the-shelf" solution already exists in the market.

There are eight pharmacy franchises registered with Korea's Fair Trade Commission (Onnuri, Medipharm, Optima, Hubase, Chamyaksa, Heaps, Parangmun, Megafactory), covering 5,405 affiliated pharmacies as of 2024 — Onnuri leads with 2,073, followed by Medipharm's 1,133 and Optima's 879. These chains have already built out multilingual service manuals, standardized SKUs, and POS and inventory systems on their own. For a duty-free operator, the simplest move is to bring in one of these as a tenant in its taxable space and collect a fixed rent — done. There's no reason for a duty-free operator to build its own MSO from scratch to develop multilingual service or inventory standardization when a proven, already-scaled brand can simply be seated in place. Even so, it's worth being explicit that a franchise headquarters' royalty structure with its affiliated pharmacies and a duty-free operator's rent from a tenant pharmacy are entirely separate contracts — and the duty-free operator's own rent still has to stay strictly fixed-fee to avoid the front-operator-pharmacy risk discussed above.

The state of regulation supports this call, too. MSO and network regulation for pharmacies only tightened in April 2026, with a follow-up rule due in July — this is a space where "the enforcement line is actively being drawn right now." Rather than building a brand-new MSO from scratch in a space this regulatorily fluid, taking a tenant slot in an already-established chain brand is the more risk-adjusted choice for duty-free operators. (The dermatology channel is the opposite case — there's no nationwide registered franchise there, and MSOs are a far more established industry practice, giving duty-free operators a much stronger incentive to build and run their own MSO directly. That's covered in Part 2.)

Business Case Summary

• Demand fit — High: Foreign tourist traffic is already captured inside duty-free stores. It overlaps directly with K-pharmacy-tour demand, meaning no new customer-acquisition cost
• Timing — High: Lines up exactly with duty free's current push to make "extending dwell time" the core of its diversification strategy amid a structural industry crisis
• Legal feasibility — Medium-high: Using taxable, non-bonded space rather than the licensed duty-free zone removes any obstacle under customs law — the Gourmet Bridge F&B leasing precedent already exists. But the Pharmacy Act's one-pharmacist-one-pharmacy principle still applies fully, so the duty-free operator must stay in a landlord or MSO role
• Economics — Medium: Because revenue-linked rent is off the table, rental income alone is more limited than the retail-industry average. A more realistic model compensates through the resulting lift in cosmetics and luxury sales from longer dwell time, plus the buzz and PR value of "there's a K-pharmacy inside the duty-free store"
• Optimal structure — Lease, not a proprietary MSO: Since registered franchises (Onnuri, Medipharm, Optima, and others) already operate 5,405 stores, duty-free operators don't need to build a new MSO — bringing in an existing chain as a tenant and collecting fixed rent is the more efficient path
• Bottom line: The opportunity is real. But there's exactly one condition for success — structure the contract on fixed rent or a fixed fee, and resist the temptation of a revenue-linked structure

Practical Takeaways

• Corporate planning (pharma, retail, and investment capital): Rather than pursuing an M&A path to directly own and operate pharmacies, actively consider setting up an MSO entity providing multilingual service, tax-refund administration, joint marketing, and inventory standardization as a service — this transplants a model already proven in the hospital and dermatology-clinic industry into the pharmacy channel, and is effectively the only legal scale-up path currently available
• MSO design and legal teams: Structure MSO contracts strictly on a fixed-fee basis, and eliminate from the contract, at the source, any element that could read as "operational control" — profit-sharing tied to pharmacy earnings, direct injection of operating capital, or decision-making power over hiring and firing staff. If Rep. Jeon's bill passes, local government heads will directly review contract terms as part of registration screening, so existing contracts need a pre-emptive review as well
• Duty-free business development and merchandising: Rather than building a new proprietary MSO, bringing in one of the FTC-registered franchises (eight chains including Onnuri, Medipharm, and Optima, covering 5,405 stores) as a tenant in taxable space is faster and lower-risk. Multilingual service and SKU standardization are already handled by the chain headquarters — duty-free operators just need to focus on a fixed-rent contract and clear physical and accounting separation from the licensed bonded sales area
• Pharma marketing and sales: Fold brand standardization — display guidelines, multilingual point-of-sale materials, ingredient recommendation scripts — into the MSO's service menu, combining brand strategy with MSO infrastructure into a dual strategy for tying individual pharmacies together
• Individual pharmacies and pharmacist associations: Pharmacies in tourist zones like Myeongdong and Hongdae should move quickly on tax-refund business registration and immediate-refund terminal adoption. Registration status itself is becoming the dividing line for tourist revenue
• Policy and legal teams: Complete legal review, within the six-month grace period, of how the amended Pharmacy Act's "under any name" clause and Rep. Jeon's proposed registration-rejection criteria apply to existing MSO and joint-marketing contracts
• Tourism infrastructure and local government (tourist-zone management): Consider supporting shared infrastructure that individual pharmacies can't build on their own — multilingual pharmacy maps, translated ingredient and efficacy materials — at the municipal or tourism-authority level; within a regulatory structure built around individual pharmacies, this kind of public infrastructure becomes, alongside MSOs, another way to manufacture economies of scale

Conclusion

The "K-pharmacy tour" is one of the fastest-growing channels in Korean retail right now. But this growth is following a different path than the usual retail boom. The familiar scale-up formula — chain consolidation backed by capital — is structurally blocked by the Pharmacy Act, and that block is tightening right as tourist demand explodes. The one remaining channel is the MSO model already validated by the hospital and dermatology-clinic industry, and even that now faces follow-up regulation, like Rep. Jeon's bill, scrutinizing the contract structure itself, demanding careful design. The timing works for a struggling duty-free industry to enter this market through its taxable space — but in the pharmacy channel specifically, there's no need to build a new MSO: bringing in an already-proven franchise chain as tenant and holding the line on fixed rent is enough. The winner in this market's next phase won't be whoever adds the most stores — it will be whoever can legally manufacture economies of scale, through brand and infrastructure, on top of a fragmented structure of individual pharmacies. Whether duty-free operators can apply this same taxable-space strategy to dermatology clinics too — and why the answer flips to the opposite conclusion (build your own MSO) in that case — is covered in the following Part 2.